Major Depressive Disorder Clinical Trials 2023

What are the top hospitals conducting major depressive disorder research?

When it comes to advancing our understanding and treatment options for major depressive disorder (MDD), several hospitals are leading the way in clinical trials. In Orlando, APG Research, LLC is making strides with five active MDD trials and a total of five trials dedicated to this condition. While relatively new in the field, having recorded their first trial in 2018, their commitment to research shows promise for future breakthroughs. The University of Connecticut Health Center in Farmington has also been actively involved in MDD research since its initial trial back in 2003. With four ongoing trials and a cumulative count of nine completed studies, this institution is contributing significantly to the fight against depression.

Moving on to Chicago, we find the Chicago Research Center playing an important role with four active MDD trials and eleven previously conducted studies since their first recorded trial in 2007. They continue working tirelessly towards improving treatments for individuals living with MDD. Another facility making notable contributions is Baber Research Group located in Naperville. Although they have only been conducting MDD trials since 2012, they already have an impressive track record of nine past studies alongside their current involvement with four ongoing investigations.

Lastly but no less significant is Lehigh Center for Clinical Research situated at Allentown; despite being geographically smaller they contribute immensely through twenty-four previous experiments while currently hosting fouroperationalresearches concerning Major Depressive Disorder; retroactively starting from as early as year2006

These hospitals serve as beacons of hope for those suffering from major depressive disorder by dedicating substantial resources towards finding innovative solutions and enhancing patient outcomes. Through collaborative efforts between medical professionals and participants willing to volunteer for these clinical trials, we can pave the way toward improved treatments and a brighter future for individuals battling MDD worldwide

Which are the best cities for major depressive disorder clinical trials?

When it comes to clinical trials for major depressive disorder, several cities have emerged as hubs of research and innovation. Miami, Florida leads the pack with 18 active trials exploring treatments like Aticaprant, Seltorexant, and REL-1017. New york, New York and Dallas, Texas trail closely behind with 15 ongoing studies investigating therapeutic options such as Aticaprant and Tianeptine Sodium in New York; Aticaprant, Seltorexant, and Strategy 1 in Dallas. Other notable cities include Orlando, Florida with 13 active trials focusing on medications like Seltorexant and TNX-601 ER; and Houston, Texas with 12 ongoing studies examining NRX-101 and Esketamine among others. These cities provide individuals suffering from major depressive disorder access to cutting-edge clinical trials that offer hope for new treatment approaches.

Which are the top treatments for major depressive disorder being explored in clinical trials?

Exciting breakthroughs in the treatment of major depressive disorder are emerging from ongoing clinical trials. Leading the charge is ketamine, with its remarkable track record of 54 all-time trials and active involvement in five current studies since its introduction in 2006. Aticaprant, a newcomer to the scene, shows promise with three active trials dedicated to major depressive disorder since it was first listed in 2022. Seltorexant and psilocybin each have three active trials under their belt as well, contributing to their growing popularity among researchers exploring new avenues for treating this debilitating condition. Lastly, Left Dorsolateral Prefrontal Cortex (L-DLPFC) is making waves with two ongoing trials that focus on unlocking its potential against major depressive disorder. With these innovative treatments paving the way forward, hope shines brighter than ever for those grappling with this challenging mental health issue.

What are the most recent clinical trials for major depressive disorder?

Recent clinical trials offer promising prospects for individuals grappling with major depressive disorder. One notable trial investigates the efficacy of esketamine, a derivative of ketamine, in treating this debilitating condition. Additionally, combining ketamine with perampanel shows potential as an innovative treatment approach for major depressive disorder. Another study explores the benefits of high CBD [25:1] medication in alleviating symptoms associated with this mental health condition. Furthermore, omega-3 supplementation is being examined as a possible adjunctive therapy to traditional treatments for major depressive disorder. Lastly, venlafaxine demonstrates promise in managing symptoms and improving overall quality of life for those affected by major depressive disorder. These clinical trials open doors to new therapeutic options that may bring relief and hope to individuals navigating this challenging illness.

What major depressive disorder clinical trials were recently completed?

Recent clinical trials have made significant strides in the field of major depressive disorder research. In June 2022, Alto Neuroscience successfully completed a trial for ALTO-100 PO Tablet, followed by two more trials for the same medication in December 2021. Neurocrine Biosciences also achieved an important milestone with their NBI-1065846 trial in November 2021. Other notable completed studies include Cerevel Therapeutics' CVL-354 trial in October 2021 and Praxis Precision Medicines' PRAX-114 study in June 2021. These advancements highlight the ongoing efforts to uncover innovative approaches for better managing major depressive disorder and improving patients' quality of life.